Partners

The Global Antibiotic Research and Development Partnership (GARDP), the Foundation for Innovative New Diagnostics (FIND), and the World Health Organization (WHO) have signed a memorandum of understanding to explore joint initiatives that could improve the sustainable access to antibiotics and protect them against the emergence of antimicrobial resistance (AMR), with an initial focus on sexually transmitted infections (STIs).

GARDP welcomes Germany’s increased commitment to preventing and combatting global pandemics through funding to accelerate the development of new treatments for drug-resistant serious bacterial infections in hospitalized people.

GENEVA – The Global Antibiotic Research and Development Partnership (GARDP) has announced a collaboration with Bugworks Research Inc (“Bugworks”), an Indo-USA-Australian biopharmaceutical group developing new … GARDP and Bugworks Research Inc sign MOU to explore antibiotic development to tackle serious bacterial infections in high-burden countries

GARDP and the University of Queensland have announced an expansion of their partnership to tackle the growing global threat of serious bacterial infections.

GARDP has today announced an agreement with Swiss biopharmaceutical company BioVersys to explore opportunities to accelerate the research and development of antibiotics for serious bacterial infections.

GARDP and Venatorx Pharmaceuticals today announced a collaboration to accelerate the development of cefepime-taniborbactam, an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).

GARDP has today announced an agreement with Daiichi Sankyo for GARDP to access and screen the Daiichi Sankyo chemical library. The library will be tested by Institut Pasteur Korea with the goal of discovering novel antibacterial compounds.

BERLIN – The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce continued support from the Dutch Ministry of Health, Welfare and Sport. … Dutch Ministry of Health, Welfare and Sport renews commitment to support GARDP

BERLIN – Today the UK government announced £3.5 million of funding to develop new treatments for gonorrhoea. It will enable global access, including in low-and … UK government invests in global partnership to treat gonorrhoea

GARDP and Entasis Therapeutics (NASDAQ: ETTX) today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhoea. Following positive phase 2 results previously published in the New England Journal of Medicine (NEJM), Entasis and GARDP have partnered to complete late stage development, with GARDP fully-funding and sponsoring the global phase 3 trial.